Katherine Rielly-Gauvin
Director/Board Member bij LIQUIDIA CORPORATION
Vermogen: - $ op 31-03-2024
Profiel
Katherine Rielly-Gauvin is an Independent Director at Liquidia Technologies, Inc. and Liquidia Corp.
She previously served as Vice President-Global Commercial Development at AbbVie, Inc. and as VP & General Manager-Commercial CNS at Janssen Pharmaceuticals, Inc. She received an undergraduate degree from Simmons University and an MBA from Rutgers University-Newark.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
LIQUIDIA CORPORATION
-.--% | 19-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Katherine Rielly-Gauvin
Bedrijven | Functie | Begin |
---|---|---|
ABBVIE INC. | Corporate Officer/Principal | 01-01-2013 |
LIQUIDIA CORPORATION | Director/Board Member | 28-06-2020 |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Director/Board Member | 30-10-2019 |
Eerdere bekende functies van Katherine Rielly-Gauvin
Bedrijven | Functie | Einde |
---|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | - |
Opleiding van Katherine Rielly-Gauvin
Simmons University | Undergraduate Degree |
Rutgers University- Newark | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ABBVIE INC. | Health Technology |
LIQUIDIA CORPORATION | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |